Given the low frequency of CD274 somatic mutations in those cancer types (0.4%; 4 mutations in 998 patients, Supplementary Dataset S1X), as compared to TP53, a prominent driver cancer gene (Supplementary Dataset S1Y), the findings highlight that even rare mutations can have significant clinical implications. This evidence concerns the gene CD274 and cancer.